NCT06948942

Brief Summary

Interstitial lung diseases (ILD) are a group of chronic respiratory diseases that cause significant mortality and morbidity worldwide. Although there are studies in the literature comparing different lung disease groups with healthy individuals, it has been determined that there is no study comparing the exercise capacity, muscle oxygenation, physical activity level, respiratory functions, respiratory and peripheral muscle strength, inspiratory muscle endurance, quality of life and sleep quality of individuals diagnosed with ILD with healthy individuals.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 12, 2024

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

April 22, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 29, 2025

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 12, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 12, 2025

Completed
Last Updated

April 29, 2025

Status Verified

February 1, 2025

Enrollment Period

7 months

First QC Date

April 22, 2025

Last Update Submit

April 22, 2025

Conditions

Keywords

Interstitial lung diseasesHealthy individualsExercise capacityMuscle oxygenationPhysical activity level

Outcome Measures

Primary Outcomes (3)

  • Maximal exercise capacity

    Maximal exercise capacity will be assessed by symptom-limited cardiopulmonary exercise testing on a treadmill at gradually increasing workload, and oxygen consumption will be measured during the test.

    Trough study completion, an average of 1 year

  • Muscle Oxygenation

    Muscle oxygenation before, during and after exercise tests will be measured with a near-infrared spectroscopy device.

    Trough study completion, an average of 1 year

  • Physical Activity Level

    Individuals' physical activity level will be assessed with a multi-sensor physical activity monitor.

    Trough study completion, an average of 1 year

Secondary Outcomes (13)

  • Upper extremity functional exercise capacity

    Trough study completion, an average of 1 year

  • Lower extremity functional exercise capacity

    Trough study completion, an average of 1 year

  • Dyspnea

    Trough study completion, an average of 1 year

  • Respiratory Muscle Strength

    Trough study completion, an average of 1 year

  • Inspiratory muscle endurance

    Trough study completion, an average of 1 year

  • +8 more secondary outcomes

Study Arms (2)

Patients with ILD

That group consists of patients who had been diagnosed with ILD by doctors. Oxygen consumption using CPET, muscle oxygenation with a near-infrared spectroscopy device, physical activity level using multi-sensor activity monitor, pulmonary function using spirometer, lower extremity functional exercise capacity with 6MWT, upper-extremity functional exercise capacity with 6PBRT, respiratory muscle strength using mouth pressure device, peripheral muscle strength with hand-held dynamometer, inspiratory muscle endurance using incremental threshold loading test, dyspnea with 'Modified Medical Research Council' Dyspnea Scale and 'Turkish version of London Chest Daily Living Activity Scale', dyspnea at rest, during, and after exercise training with 'Modified Borg Scale', disease-related quality of life with 'Turkish version of Saint George Respiratory Questionnaire' and sleep quality with 'Pittsburg Sleep Quality Index' will be evaluated in patients with ILD.

Healthy Controls

That group consists of people who have not been diagnosed with a disease. Oxygen consumption using CPET, muscle oxygenation with a near-infrared spectroscopy device, physical activity level using multi-sensor activity monitor, pulmonary function using spirometer, lower extremity functional exercise capacity with 6MWT, upper-extremity functional exercise capacity with 6PBRT, respiratory muscle strength using mouth pressure device, peripheral muscle strength with hand-held dynamometer, inspiratory muscle endurance using incremental threshold loading test, dyspnea with 'Modified Medical Research Council' Dyspnea Scale and 'Turkish version of London Chest Daily Living Activity Scale', dyspnea at rest, during, and after exercise training with 'Modified Borg Scale', disease-related quality of life with 'Turkish version of Saint George Respiratory Questionnaire' and sleep quality with 'Pittsburg Sleep Quality Index' will be evaluated in healthy controls.

Eligibility Criteria

Age18 Years - 75 Years
Sexall(Gender-based eligibility)
Gender Eligibility DetailsFemale and Male
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients diagnosed with ILDs and healthy individuals

You may qualify if:

  • Patients diagnosed with ILD according to ATS/ERS criteria,
  • Ages between 18 and 75,
  • Pulmonary infection during the previous month,
  • Participants who voluntarily participated in the study were included.

You may not qualify if:

  • Patients were excluded if they had:
  • Acute pulmonary exacerbation or respiratory infection in the last four weeks
  • Obstructive lung disease
  • Systemic conditions affecting neurological, neuromuscular, orthopedic, or physical functions
  • Recent participation in a planned exercise program (within three months)
  • Cognitive impairment affecting exercise test understanding
  • Contraindications to exercise testing per the American Sports Medicine Association
  • Cancer, renal, or hepatic disease
  • Aortic stenosis, complex arrhythmia, or aortic aneurysm
  • Serious cardiovascular diseases like uncontrolled hypertension, diabetes, heart failure, or arrhythmia
  • For healthy individuals who will participate in the study;
  • No diagnosed chronic disease,
  • Healthy adults between the ages of 45-80
  • Individuals with a Mini Mental State Assessment Scale score of less than 24,
  • A smoking history of at least 10 packs×years or more,
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gazi University Faculty of Health Sciences Department of Physiotherapy and Rehabilitation, Cardiopulmonary Rehabilitation Unit

Ankara, 06490, Turkey (Türkiye)

RECRUITING

Related Links

MeSH Terms

Conditions

Lung Diseases, Interstitial

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract Diseases

Study Officials

  • Meral BOŞNAK GÜÇLÜ, Prof. Dr.

    Gazi University

    STUDY DIRECTOR
  • Nazire Nur YILDIZ, M.Sc.

    Nigde Omer Halisdemir University

    PRINCIPAL INVESTIGATOR
  • Meral BOŞNAK GÜÇLÜ, Prof. Dr.

    Gazi University

    PRINCIPAL INVESTIGATOR
  • Beyzanur ÖYMEZ

    Gazi University

    PRINCIPAL INVESTIGATOR
  • Ayşenur GÜVENİR, M.Sc.

    Yozgat Bozok University

    PRINCIPAL INVESTIGATOR
  • Nilgün YILMAZ DEMİRCİ, Prof. Dr.

    Gazi University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Meral BOŞNAK GÜÇLÜ, Prof. Dr.

CONTACT

Nazire Nur YILDIZ, M.Sc.

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr.

Study Record Dates

First Submitted

April 22, 2025

First Posted

April 29, 2025

Study Start

December 12, 2024

Primary Completion

July 12, 2025

Study Completion

September 12, 2025

Last Updated

April 29, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

To protect patient data, it will not be shared.

Locations